Cancer

Add us on Google

How Often Should You Take the Galleri Test?

GRAIL, the maker of Galleri, supports taking the test once a year alongside recommended cancer screening. Galleri is not in screening guidelines, so here is what one result can and cannot tell you, what the repeat-testing evidence shows, and how to decide on timing.

Published

October 20, 2026

Read time

11 min read

Medically reviewed by

Rhonda Collins, FNP-C

Share

Copy link

Summarize with AI

GRAIL, the company that makes Galleri, supports taking the test once a year as an addition to recommended cancer screening. That annual cadence is the manufacturer’s position, not a guideline: Galleri is not included in cancer screening guidelines [1]. Each Galleri result describes only the blood drawn that day, so whether and when to test again is an individual decision to make with a clinician.

The sections below explain why one result cannot stand in for the next, what the evidence on repeat Galleri testing does and does not show, and how to work out timing.

What does a Galleri result tell you?

A Galleri result is a snapshot of the cancer signals present in one blood sample at the time of the draw. Galleri looks for DNA fragments that cancer cells shed into the bloodstream, and reads their methylation patterns to screen for the current presence of cancer [1]. For how this family of tests works more broadly, see what a multi-cancer early detection (MCED) test is.

The two possible results mean different things [2]:

• No Cancer Signal Detected means the test did not find DNA fragments associated with cancer in that sample. GRAIL states that this result does not completely rule out the possibility of cancer.
• Cancer Signal Detected means the test found DNA fragments associated with cancer. GRAIL states that this is not a cancer diagnosis and requires follow-up diagnostic testing.

False positive and false negative results both occur. How often each happens is a question about Galleri’s accuracy, which is separate from how often to take it.

Why can’t last year’s Galleri result answer this year’s question?

A Galleri result from last year describes last year’s blood sample. It cannot say whether a cancer has started, or grown large enough to shed a detectable signal, in the months since that draw.

The National Cancer Institute (NCI) explains that the DNA changes behind cancer, whether caused by a random mistake or by a carcinogen, can happen throughout life [3]. A No Cancer Signal Detected result is therefore not a forecast. It does not predict that cancer will not develop later, and it does not measure a person’s future risk. This is the reason GRAIL frames Galleri as a repeated test rather than a one-time one.

Is cancer inherited or acquired, and why does it matter for retesting?

Cancer is a genetic disease, but most of the genetic changes that cause it are not inherited. NCI states that up to 10% of all cancers may be caused by inherited genetic changes. The vast majority occur by chance over time, as random mistakes happen while cells multiply or as carcinogens such as the chemicals in tobacco smoke alter DNA [3].

This distinction separates two kinds of test that are easy to confuse:

GRAIL draws the same line: germline tests look for inherited mutations that raise future risk and are usually done once, while Galleri screens for the current presence of cancer [1]. A normal germline result does not mean cancer is absent, and a No Cancer Signal Detected Galleri result does not mean inherited risk is low. For people with a strong family history, NCI notes that a genetic counselor can help weigh the risks, benefits, and drawbacks of genetic testing. Our article on how ancestry, genetics, and aging shape cancer risk covers that side in more depth.

What does GRAIL say about annual Galleri testing?

GRAIL tells patients that Galleri “can be taken as a simple annual blood test” and to ask their healthcare provider when it is best to test again [2]. In its provider materials, GRAIL states that adding annual Galleri testing to recommended cancer screenings offers an increased opportunity for early detection, and that real-world evidence supports annual screening [1].

GRAIL also defines who the test is for. Galleri is recommended for adults with an elevated risk of cancer, such as those aged 50 or older. GRAIL does not recommend it for people who are pregnant, who are 21 or younger, or who are undergoing active cancer treatment [1]. Those criteria apply to every repeat test as well as the first, so a change such as a pregnancy or the start of cancer treatment changes whether another test is appropriate.

These are the manufacturer’s statements. They are not the same as a recommendation from an independent guideline body.

What does the evidence on repeat Galleri testing show?

The evidence shows that repeat Galleri testing finds some cancers after an earlier negative result, often at an early stage. It does not yet show that annual testing reduces cancer deaths, or which interval between tests is best.

GRAIL’s real-world repeat-testing data. At the 2024 meeting of the American Association for Cancer Research (AACR), GRAIL-affiliated researchers presented early data on 5,794 people whose first Galleri result was No Cancer Signal Detected and who had a second test by August 2023 [4]:

• 56% of repeat tests were taken 10 to 14 months after the first, and 81% within 10 to 18 months.
• 26 repeat tests (0.45%) returned Cancer Signal Detected, compared with 1.1% of 47,016 first tests.
• Of the 21 people whose clinical outcome was known, 12 were diagnosed with cancer and 9 were not. Five were still under investigation.
• Stage was known for 6 of the 12 cancers, and 5 of those 6 were stage 0 or stage I.

The authors call these data preliminary and descriptive. They note that people who choose repeat testing may be unusually health conscious, a “healthy volunteer effect” that is well documented in cancer screening studies. The cohort had no comparison group, so it cannot show whether repeat testing changed anyone’s outcome.

The NHS-Galleri randomized trial. The NHS-Galleri trial in England enrolled 142,250 people aged 50 to 77 and offered three annual Galleri tests. It did not meet its primary endpoint: there was no statistically significant reduction in combined stage III and stage IV cancers [5]. In a pre-specified secondary analysis, GRAIL reported 14% fewer stage IV cancers overall in the group that had Galleri. By round, the reduction was 9% in the first, 22% in the second, and 26% in the third, and only the third-round estimate was clear of the possibility of no difference [6]. The trial has not reported results on cancer deaths, and follow-up is continuing.

What earlier detection does not prove. NCI states that no multi-cancer detection test has been proven to reduce deaths from cancer, and that these tests may find slow-growing cancers that would never have affected a person’s health [7].

Is Galleri part of recommended cancer screening?

No. GRAIL states that Galleri is currently not included in cancer screening guidelines [1]. Recommended screenings stay in place whether or not someone takes Galleri. NCI states that standard-of-care cancer screenings are recommended regardless of whether a person has a multi-cancer detection test, because screenings such as those for breast, cervical, colorectal, and lung cancer have been proven to find those cancers early [7]. GRAIL likewise says Galleri should be used in addition to the screening tests a healthcare provider recommends [2].

A yearly Galleri test is never a reason to skip or delay a mammogram, colonoscopy or stool-based colorectal test, cervical screening, or lung screening for those who are eligible. For how these fit together by age, see our guide to a personalized cancer screening plan after 40.

Is another Galleri test the right next step?

Another Galleri test fits one situation: routine reconsideration after an earlier No Cancer Signal Detected result. It is not the next step in two other situations that can look similar.

How to decide when to take Galleri again

The timing of a repeat Galleri test is worth a short conversation with a clinician, because it depends on age, personal and family history, and which standard screenings are due. A few things make that conversation useful:

• Find the previous collection date and report. The date sets the starting point for an annual interval, and the report confirms which result it was. Anyone who ordered Galleri through Mito can find the earlier report in their Mito dashboard.
• Check that no earlier follow-up is still open. Any unresolved workup from a Cancer Signal Detected result comes first, as in the table above.
• Note what has changed since the last test. New symptoms, a new diagnosis, a pregnancy, or the start of cancer treatment all change the answer, and the last three can make Galleri not recommended.
• Bring the routine screening history. Galleri is an addition to those screenings, so any that are overdue are the first gap to close.
• Ask what a positive result would lead to. A Cancer Signal Detected result leads to diagnostic testing, which is worth understanding before ordering.

Through Mito, an on-demand 30-minute clinician consult is $39 with membership and $99 without, as listed on the Galleri product page on October 20, 2026.

How to reorder the Galleri test through Mito

Galleri can be reordered through Mito from the Galleri multi-cancer early detection test page. On October 20, 2026, that page listed Galleri at $636.12 with Mito membership and $890.57 without it; the product page always shows the current price. Membership is separate, at $9 per month or $99 per year, and any applicable lab order or draw fee is itemized before payment.

How the order works:

• Where: the blood draw is at a Quest Diagnostics location.
• Availability: Galleri is available through Mito in 45 states and Washington, DC. It is not currently available in Arizona, Hawaii, New Jersey, New York, or Rhode Island.
• Before checkout: a few health questions check that the test is a fit, and checkout includes GRAIL’s Patient Information Sheet, which describes what the test does, what a positive result means, and its limitations.
• Payment: Galleri is HSA/FSA eligible. Our guide to HSA/FSA-eligible health tests explains how that works.
• Results: the report appears in the Mito dashboard when it is ready.

For a broader look at the test itself, the multi-cancer early detection test guide and our comparison of Galleri and LucenceINSIGHT cover how the available MCED tests differ.

References

1. Galleri: Frequently Asked Questions (FAQs) for Providers
2. Galleri: Understanding Your Galleri Test Results
3. National Cancer Institute: The Genetics of Cancer
4. GRAIL: Abrams, AACR 2024 repeat testing oral presentation (PDF)
5. NHS-Galleri Trial: What the trial found
6. GRAIL: GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
7. National Cancer Institute: Questions and Answers about Multi-Cancer Detection Tests

Frequently asked questions

Is the Galleri test FDA approved?

No. GRAIL states that Galleri has not been cleared or approved by the FDA. On September 23, 2026, an FDA advisory committee voted in favor of GRAIL's premarket approval application for adults 50 and older, but that vote is a recommendation, and the FDA's final decision is still pending.

Can you take the Galleri test more often than once a year?

GRAIL describes Galleri as an annual test and does not give a general interval shorter than a year. The one shorter timeline GRAIL describes is a retest 3 to 6 months after a Cancer Signal Detected result when the diagnostic evaluation did not find cancer.

Does a family history of cancer mean Galleri should be taken more often?

GRAIL does not give a separate Galleri schedule for people with a family history of cancer. Galleri does not measure inherited risk, so a strong family history is better addressed with genetic counseling and the standard screening plan it may change.

Does insurance pay for a repeat Galleri test?

Most insurance plans do not yet cover multi-cancer early detection screening, so a repeat Galleri test is generally paid out of pocket. Galleri is HSA/FSA eligible when ordered through Mito.